65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

about

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q47104104

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@en

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@nl

type

Item

label

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@en

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@nl

prefLabel

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@en

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@nl

P1476

65Plus: open-label study of be ...... us non-small-cell lung cancer.

@en

P2093

Christian Schumann

http://www.w3.org/2001/XMLSchema#string

Claus-Peter Schneider

http://www.w3.org/2001/XMLSchema#string

Cornelius Kortsik

http://www.w3.org/2001/XMLSchema#string

Gert Hoeffken

http://www.w3.org/2001/XMLSchema#string

Martin Kohlhaeufl

http://www.w3.org/2001/XMLSchema#string

Martin Reck

http://www.w3.org/2001/XMLSchema#string

Monika Heidi Ursel Serke

http://www.w3.org/2001/XMLSchema#string

Walburga Engel-Riedel

http://www.w3.org/2001/XMLSchema#string

Wolfgang Schuette

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience.

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Methods for equivalence and noninferiority testing.

P304

217-229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/LCTT.S142972

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29158696

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5683796

http://www.w3.org/2001/XMLSchema#string